Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079281 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
A Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06079281: Active Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
NCT06079281 is a Phase 3 study of Hypophosphatasia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 124 participants, above the 63-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06079281, a Phase 3 study of Hypophosphatasia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN1850
Study Locations (20)
Other
- Research Site - Ciudad de Buenos Aires
- Research Site - Clayton
- Research Site - Herston
- Research Site - Parkville
- Research Site - St Leonards
- Research Site - Belo Horizonte
- Research Site - Brasília
- Research Site - Recife
- Research Site - Salvador
- Research Site - São Paulo
- Research Site - São Paulo
Alberta
- Research Site - Calgary
- Research Site - Edmonton
Indiana
- Research Site - Indianapolis
New York
- Research Site - Garden City
North Carolina
- Research Site - Durham
Ohio
- Research Site - Columbus
Tennessee
- Research Site - Nashville
Manitoba
- Research Site - Winnepeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2028-03-29 |
| Phase | Phase 3 |
What the registry record for NCT06079281 still lists
NCT06079281 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (97% higher).
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06079281 names 20 study sites across 9 states, led by Other, Alberta, Indiana.
Frequently Asked Questions
What is clinical trial NCT06079281 about?
NCT06079281 is a clinical study titled "Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa". The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
What is the current status of trial NCT06079281?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2024-01-03. Estimated completion is 2028-03-29.
What conditions does trial NCT06079281 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT06079281?
The interventions under investigation include: Placebo (DRUG), ALXN1850 (DRUG).
Who is sponsoring clinical trial NCT06079281?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079281 being conducted?
This trial has 20 study locations across Indiana, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ACTIVE NOT RECRUITING · Phase 3
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
RECRUITING
-
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI